Kinase inhibitors for the therapy of malignant melanoma;Kinaseinhibitoren zur therapie des malignen melanoms

JDDG - Journal of the German Society of Dermatology

Volumn 3, Issue 10, 2005, Pages 762-767

  Becker, Jürgen C ^a   Schrama, David ^a   Bröcker, Eva B ^a   Houben, Roland ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Kinase inhibitors; Melanoma; Signal transduction; Therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AP 23573; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; PHOSPHOTRANSFERASE;

DRUG TARGETING; ENZYME INHIBITION; GENETIC ANALYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; MOLECULAR GENETICS; ONCOGENE RAS; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TREATMENT OUTCOME; ANIMAL; APOPTOSIS; CELL SURVIVAL; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; PROTEIN SYNTHESIS; SKIN TUMOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENES, RAS; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; ONCOGENE PROTEIN V-AKT; PHOSPHOTRANSFERASES; PROTEIN BIOSYNTHESIS; SKIN NEOPLASMS;

EID: 33644701476     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2005.05016.x     Document Type: Review

References (18)

1. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4: 748-759.
2. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer. Am J Clin Pathol 2004; 122: 598-609.
3. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701.
4. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
6. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R, Rapp UR. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3: 6.
7. Gray-Schopfer VC, da Rocha DS, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005; 24: 165-183.
8. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23: 6292-6298.
9. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
10. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2004; 26: 473-503.
11. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131-137.
12. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004; 10: 2968-2976.
13. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963.
14. Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004; 64: 2552-2560.
15. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
16. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004; 16: 564-575.
17. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91: 1420-1424.
18. CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Journal of Clinical Oncology 2004; 22: 7523.